SCHEMBL2323399

SCHEMBL2323399

O=C(OCc1ccccc1)N1CCN(C2CCC(c3ncc4c(Cl)nccn34)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 7/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP2D6 P10635 4/20 0.42
CYP2C9 P11712 4/20 0.42
CYP3A4 P08684 3/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
TMEM97 Q5BJF2 6/20 0.42
SIGMAR1 Q99720 6/20 0.42
CYP2C19 P33261 1/20 0.41
HTR1A P08908 2/20 0.41
HRH2 P25021 2/20 0.41
HRH1 P35367 2/20 0.41
HRH3 Q9Y5N1 2/20 0.41
ADRA2C P18825 1/20 0.41
MGLL Q99685 2/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2323403 1.00 GRIN2B (0.43) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL593236 0.91 SMN1; SMN2 (0.50) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL2321177 0.90 GRIN2B (0.43) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL2321173 0.90 GRIN2B (0.43) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL28938318 0.85 SMN1; SMN2 (0.46) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL21050978 0.85 SMN1; SMN2 (0.46) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL2323323 0.85 OPRD1 (0.43) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL14647469 0.85 JAK2 (0.47) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL14654247 0.85 JAK2 (0.47) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6
SCHEMBL15878148 0.82 F2 (0.38) GRIN2BSMN1; SMN2NPC1RAB9ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534151-B1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MERCK SHARP & DOHME (NL) 2018-11-14 EP disclosed
US-8658794-B2 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof MERCK SHARP & DOHME B.V. (NL) 2014-02-25 US disclosed
EP-2534151-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MSD Oss B.V. (NL) 2012-12-19 EP disclosed
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2012-12-06 US disclosed
WO-2011095556-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS LCK, ZAP70, FYN GRIN2B 2177/4885SMN1; SMN2 1823/4885NPC1 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.